BCIP Life Sciences Associates, LP's Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Dec 10, 2021
- Accession no.
- 0000899243-21-047829
- Filed
- Dec 10, 2021, 8:33 PM ET
- Trade date
- Dec 8-10, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $410.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BCIP Life Sciences Associates, LPCIK 0001702921 | 10% Owner |
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences Fund II, L.P.CIK 0001773187 | 10% Owner |
| Bain Capital Life Sciences Investors II, LLCCIK 0001796155 | 10% Owner |
| BCLS II Investco, LPCIK 0001818893 | 10% Owner |
| BCLS II Investco (GP), LLCCIK 0001819101 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2021 | Common Stock | PPurchaseAcquired | +13,458 | $9.62 | +$129,474.03 | 2,776,402 | Indirect | |
| Dec 9, 2021 | Common Stock | PPurchaseAcquired | +4,011 | $9.84 | +$39,485.09 | 2,780,413 | Indirect | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +21,812 | $9.56 | +$208,564.16 | 2,802,225 | Indirect | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +3,188 | $10.24 | +$32,638.11 | 2,805,413 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.